By Josh White
Date: Thursday 04 Sep 2025
(Sharecast News) - Shield Therapeutics said on Thursday that the US Food and Drug Administration (FDA) has granted priority review to extend the indication of its oral iron therapy Accrufer/Feraccru to adolescents aged 10 and above, with potential approval expected in 2026.
By Josh White
Date: Wednesday 03 Sep 2025
(Sharecast News) - Shield Therapeutics reported a sharp rise in first-half revenue on Wednesday, as sales of its oral iron therapy Accrufer accelerated across key markets, leaving the company on track to reach cash flow breakeven by the end of 2025.
By Iain Gilbert
Date: Tuesday 22 Apr 2025
(Sharecast News) - Pharmacitucal firm Shield Therapeutics said on Tuesday that it had inked an exclusive licence agreement for its ACCRUFeR iron deficiency asset in Japan with VITAL-NET.
Currency | UK Pounds |
Share Price | 7.90p |
Change Today | -0.050p |
% Change | -0.63 % |
52 Week High | 9.00 |
52 Week Low | 2.25 |
Volume | 433,486 |
Shares Issued | 1,061.69m |
Market Cap | £83.87m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
10:12 | 5,570 @ 7.87p |
09:51 | 12,346 @ 8.10p |
09:51 | 556 @ 8.10p |
09:51 | 62,500 @ 8.00p |
09:51 | 62,500 @ 8.00p |
You are here: research